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Ca2+-calcineurin-NFAT signaling plays a major role in promoting pathological cardiac hypertrophy. Heineke
et al. (2010) show that CIB1 strongly enhances calcineurin activation and cardiac hypertrophy upon patho-
logical stress, likely by functioning as a scaffold protein that exposes calcineurin to the L-Type Ca2+ channel
and the sarcolemma.Growth of the adult mammalian heart can
be physiological (during postnatal devel-
opment and in response to pregnancy
and exercise) or pathological (in the con-
text of a cardiac disease). In either case,
growth of the heart is achieved primarily
by increasing the size (hypertrophy) of
pre-existing cardiomyocytes, with little or
no contribution of cardiomyocyte prolifer-
ation. While physiological heart growth
increases cardiac performance to match
metabolic demands, pathological heart
growth is ultimately maladaptive (Hill and
Olson, 2008) and can culminate in heart
failure, the inability of the heart to supply
sufficient blood flow and one of the
leading causes of death in industrialized
countries. Physiological and pathological
hypertrophy are mediated largely through
different extra- and intracellular signaling
pathways. Among them, a Ca2+-calci-
neurin-NFAT signaling cascade has been
identified as a crucial node where inputs
from several signaling pathways are inte-
grated to promote pathological hyper-
trophy (Molkentin et al., 1998).
In a beautifully conducted study in
Nature Medicine, Heineke and colleagues
(Heineke et al., 2010) shed new light on
how calcineurin activation can be sus-
tained by Ca2+ signals in a cellular envi-
ronment where cytosolic Ca2+ concentra-
tions continuously fluctuate to induce
cardiomyocyte contraction.
Calcineurin is a serine-threonine pro-
tein phosphatase that comprises a cata-
lytic A subunit (CnA), which can be bound
by two small EF-hand calcium-binding
proteins, the regulatory calcineurin B
subunit (CnB) and calmodulin (Crabtree
and Olson, 2002). CnB binds CnA at low
calcium concentrations; in contrast,calmodulin binds to CnA only at
higher cytosolic calcium concentrations,
for example during cardiac stress. This
activates the phosphatase activity of
CnA by inducing a conformational change
that separates an autoinhibitory domain
from the active enzymatic site. Active
calcineurin dephosphorylates nuclear
factor of activated T cells (NFAT),
which results in translocation of NFAT
from the cytoplasm to the nucleus, where
it promotes hypertrophic gene expression
(Figure 1).
Heineke and colleagues show now that
calcineurin activation is enhanced upon
compartmentalization of calcineurin to
the sarcolemma, the cell membrane of
the cardiomyocyte, possibly by directly
exposing the calcineurin protein complex
to Ca2+ influx through the L-type Ca2+
channel. They further show that binding
of calcineurin to the sarcolemma is
promoted through a scaffold protein,
Ca2+- and integrin-binding protein-1
(CIB1, calmyrin), that is specifically upre-
gulated during pathological, but not
physiological cardiac hypertrophy. Upon
pathological stress, CIB1 localizes to the
sarcolemma of murine and human cardio-
myocytes, where it can bind to L-Type
Ca2+ channels and seems to function as
an anchor that facilitates binding of CnB
to the sarcolemma (Figure 1).
Cib1 knockout mice undergoing
thoracic aortic constriction (TAC) surgery,
a model of pathological hypertrophy in
which the heart is exposed to acute
hypertension secondary to ligation of the
thoracic aorta, had a blunted hypertrophic
response, reduced induction of hypertro-
phic marker genes, and less fibrosis
compared to wild-type mice. Conversely,Cell Metabolism 12, Sinducible overexpression of CIB1 in the
hearts of adult transgenic mice enhanced
cardiac hypertrophy in response to TAC,
which was reversed in a CnA knockout
background. These results suggest that
pharmacological inhibition of CIB1 could
be a means to specifically suppress path-
ological cardiac hypertrophy. However,
since CIB1 is expressed in a wide variety
of tissues, CIB1 inhibitors likely would
have to be cardiac-specific to circumvent
side effects in other tissues such as im-
paired angiogenesis following ischemia,
impaired thrombosis, or male sterility, all
of which were observed in Cib1 knockout
mice (Naik et al., 2009; Yuan et al., 2006;
Zayed et al., 2007).
Two calcineurin inhibitory drugs, cyclo-
sporin A (CsA) and tacrolimus/FK506,
have been used since the 1980s to sup-
press T cell immunity and prevent graft
rejection in organ transplantation. By
blocking calcineurin in the heart, they are
believed to also suppress pathological
cardiac hypertrophy (at least in mice).
However,CsA also causes kidneydamage
and hypertension, a primary cause of
cardiac hypertrophy, which further high-
lights the need to develop cardiac-specific
inhibitors of calcineurin-NFAT signaling.
It is unclear whether the CIB1-CnB in-
teraction plays a role in other tissues.
However, if the CIB1-CnB interaction
were cardiac-specific, inhibition of this
interaction might be a promising pharma-
cologic approach. One the other hand,
it is also unclear whether the observed
prohypertrophic effects of CIB1 were
mediated solely via binding to calcineurin.
CIB1 was shown to also interact with
several other signaling molecules, how-
ever, so far only in noncardiomyocytes.eptember 8, 2010 ª2010 Elsevier Inc. 205
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Figure 1. Model of CIB1-Induced Activation of Calcineurin-NFAT Signaling
Upon pathological cardiac stress, cytosolic Ca2+ concentration increases, due to enhanced Ca2+ influx through the L-Type Ca2+-channel (yellow). Elevated intra-
cellular Ca2+ concentrations lead to Ca2+ binding of CIB1, inducing a conformational change of this scaffold protein that likely replaces ASK1with calcineurin (Cn)
as a binding partner. Unbound ASK1might get activated by autophosphorylation and promote apoptosis, while the Ca2+-CIB1-calcineurin complex interacts with
the sarcolemma and the L-Type Ca2+-channel. This seems to be a prerequisite to allow calcineurin activation by binding of Ca2+ loaded calmodulin. Activated
calcineurin dephosphorylates NFAT resulting in its nuclear translocation, induction of hypertrophic gene expression and eventually cardiomyocyte hypertrophy.
ASK1, apoptosis signal-regulating kinase1; CIB1, Ca2+ and integrin-binding protein-1; CnB, calcineurin B (regulatory calcineurin domain); CnA, calcineurin A
(catalytic calcineurin domain), NFAT, nuclear factor of activated T cells.
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calcineurin-NFAT signaling by specific
disruption of the CIB1-CnB interaction
might be advantageous compared to
direct inhibition of calcineurin, since
Cib1 knockout mice do not seem to
have a basal cardiac phenotype, while
cardiac-specific deletion of CnB resulted
in impaired cardiac function during post-
natal cardiac development (Schaeffer
et al., 2009).
Recently, CIB1 was also shown to
interact with apoptosis signal-regulating
kinase1 (ASK1) (Yoon et al., 2009), which
is believed to regulate cardiomyocyte
apoptosis (Liu et al., 2009). CIB1 binding
of ASK1 blocks autophosphorylation of
ASK1 and thereby its activation. In
response to an increase in intracellular
Ca2+, CIB1 dissociates from ASK1,
inducing its activation in neurons. One
could speculate that under basal condi-
tions CIB1 also binds and inhibits ASK1
in cardiomyocytes. Ca2+ binding of CIB1
upon a stress-induced Ca2+ increase
would then function as a switch that acti-
vates ASK1 and calcineurin simulta-
neously by replacing ASK1 with CnB as
a binding partner for CIB1.206 Cell Metabolism 12, September 8, 2010 ªIn summary, Heineke et al. (2010) iden-
tified CIB1 as a crucial prohypertrophic
activator of calcineurin-NFAT signaling.
Inhibition of CIB1-dependent calcineurin
activation might be an interesting phar-
macologic approach to treat pathological
cardiac hypertrophy; however, develop-
ment of such inhibitors could be chal-
lenging since CIB1 does not possess an
intrinsic enzymatic activity but, instead,
works through protein-protein interaction.
The plethora of regulatory inputs into the
calcineurin-NFAT pathway offers many
opportunities (and challenges) to the ther-
apeutic manipulation of this signaling
axis in the setting of pathological cardiac
hypertrophy. However, for now, preven-
tion of pathological hypertrophy by
rigorous treatment of risk factors such
as arterial hypertension, aortic stenosis,
or coronary artery disease remains the
best means to treat this lethal disorder.REFERENCES
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